This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Idera Pharmaceuticals, Inc.
Drug Names(s): GEM 231
Description: GEM 231 is a second generation antisense compound for treating solid tumor cancers. GEM 231 is designed to inhibit the regulatory subunit R1alpha of Protein Kinase A, or PKA, which has been shown to be present at increased levels in the cells of many human cancers. GEM 231 has been shown to have preclinical anti-tumor activity in models of various types of cancer, alone and in combination with various agents.
GEM 231 News
Pink Sheet Weekly Trademark Review Jan. 31, 2017
Additional information available to subscribers only: